

On page 2, delete the 2<sup>nd</sup> full paragraph, and replace this paragraph with the following in accordance with 37 CFR §1.121. A marked up version showing changes is attached:

Preliminary investigations determined that tryptic casein phosphopeptides contributed to the anticariogenic activity and this was made subject of US Patent No. 5,015,628. In particular, peptides Bos  $\alpha_{s1}$ -casein X-5P (f59-79) (SEQ ID NO: 1), Bos  $\beta$ -casein X-4P (f1-25) (SEQ ID NO: 2), Bos  $\alpha_{s2}$ -casein X-4P (f46-70) (SEQ ID NO: 3) and Bos  $\alpha_{s2}$ -casein X-4P (f1-21) (SEQ ID NO: 4) were disclosed in US Patent 5,015,628 as follows:

- (SEQ ID NO: 1)      Gln<sup>59</sup>-Met-Glu-Ala-Glu-Ser(P)-Ile-Ser(P)-Ser(P)-Ser(P)-Glu-Ile-Val-Pro-Asn-Ser(P)-Val-Glu-Gln-Lys<sup>79</sup>.       $\alpha_{s1}$ (59-79)
- (SEQ ID NO: 2)      Arg<sup>1</sup>-Glu-Leu-Glu-Glu-Leu-Asn-Val-Pro-Gly-Glu-Ile-Val-Glu-Ser(P)-Leu-Ser(P)-Ser(P)-Ser(P)-Glu-Glu-Ser-Ile-Thr-Arg<sup>25</sup>.       $\beta$ (1-25)
- (SEQ ID NO: 3)      Asn<sup>46</sup>-Ala-Asn-Glu-Glu-Glu-Tyr-Ser-Ile-Gly-Ser(P)-Ser(P)-Ser(P)-Glu-Glu-Ser(P)-Ala-Glu-Val-Ala-Thr-Glu-Glu-Val-Lys<sup>70</sup>.       $\alpha_{s2}$ (46-70)
- (SEQ ID NO: 4)      Lys<sup>1</sup>-Asn-Thr-Met-Glu-His-Val-Ser(P)-Ser(P)-Ser(P)-Glu-Glu-Ser-Ile-Ile-Ser(P)-Gln-Glu-Thr-Tyr-Lys<sup>21</sup>.       $\alpha_{s2}$ (1-21)

# IN THE CLAIMS

Please cancel claims 8, 12, 13, 27, 28, 39 and 40, without prejudice or disclaimer.

In accordance with 37 CFR §1.121, please substitute for original claims 1, 4, 7, 9-11, 15 and 25, the following rewritten versions of the same claims, as amended. The changes are shown explicitly in the attached "Version with Markings to Show Changes Made."

11/28/2001 YPOLITE1 00000012 09380738

02 FC:103

108.00 OP